DE60230807D1 - Behandlung von sarkom bei menschen mit adenovirus-vektor tnf-alpha - Google Patents
Behandlung von sarkom bei menschen mit adenovirus-vektor tnf-alphaInfo
- Publication number
- DE60230807D1 DE60230807D1 DE60230807T DE60230807T DE60230807D1 DE 60230807 D1 DE60230807 D1 DE 60230807D1 DE 60230807 T DE60230807 T DE 60230807T DE 60230807 T DE60230807 T DE 60230807T DE 60230807 D1 DE60230807 D1 DE 60230807D1
- Authority
- DE
- Germany
- Prior art keywords
- human
- dose
- tnf
- sarcoma
- alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/001,017 US20030086903A1 (en) | 2001-11-02 | 2001-11-02 | Therapeutic regimen for treating cancer |
US10/151,633 US7214368B2 (en) | 2001-11-02 | 2002-05-17 | Therapeutic regimen for treating cancer comprising the administration of adenoviral vectors comprising a TNF-α transgene |
PCT/US2002/035042 WO2003039458A2 (en) | 2001-11-02 | 2002-11-01 | TREATMENT OF HUMAN CANCER WITH ADENOVIRAL VECTOR EXPRESSING TNF-α |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60230807D1 true DE60230807D1 (de) | 2009-02-26 |
Family
ID=21693977
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60230807T Expired - Lifetime DE60230807D1 (de) | 2001-11-02 | 2002-11-01 | Behandlung von sarkom bei menschen mit adenovirus-vektor tnf-alpha |
Country Status (7)
Country | Link |
---|---|
US (5) | US20030086903A1 (de) |
EP (1) | EP1455840B1 (de) |
JP (1) | JP2005536447A (de) |
AT (1) | ATE419875T1 (de) |
CA (1) | CA2465361A1 (de) |
DE (1) | DE60230807D1 (de) |
WO (1) | WO2003039458A2 (de) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6579522B1 (en) * | 2000-06-27 | 2003-06-17 | Genvec, Inc. | Replication deficient adenoviral TNF vector |
US8071740B2 (en) * | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
AU2003222427B8 (en) | 2000-11-17 | 2010-04-29 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
US8034791B2 (en) * | 2001-04-06 | 2011-10-11 | The University Of Chicago | Activation of Egr-1 promoter by DNA damaging chemotherapeutics |
JP4173446B2 (ja) | 2001-10-19 | 2008-10-29 | ヴァスキュラー バイオジェニックス リミテッド | 血管形成の標的化されたダウンレギュレーションおよび抗ガン治療のためのポリヌクレオチド構築物および薬学的組成物および方法 |
US20030086903A1 (en) * | 2001-11-02 | 2003-05-08 | Genvec, Inc. | Therapeutic regimen for treating cancer |
WO2004093820A2 (en) * | 2003-04-23 | 2004-11-04 | University Of Massachusetts | Methods and compositions for solid tumor treatment |
US20050027196A1 (en) * | 2003-07-30 | 2005-02-03 | Fitzgerald Loretta A. | System for processing patient radiation treatment data |
ATE458500T1 (de) | 2003-11-14 | 2010-03-15 | Genvec Inc | Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc). |
BRPI0507690A (pt) | 2004-02-12 | 2007-07-24 | Neovista Inc | métodos e aparelho para a braquiterapia intra-ocular |
ES2353606T3 (es) * | 2004-08-25 | 2011-03-03 | The University Of Chicago | Uso de la combinación que comprende temozolomida y tnf-alfa para el tratamiento del gioblastoma. |
US8586090B2 (en) * | 2004-10-05 | 2013-11-19 | Albert Einstein College Of Medicine Of Yeshiva University | Melanin nanoshells for protection against radiation and electronic pulses |
CA2629648A1 (en) | 2005-11-15 | 2007-05-24 | Neovista Inc. | Methods and apparatus for intraocular brachytherapy |
WO2007149938A2 (en) * | 2006-06-21 | 2007-12-27 | The Salk Institute Biological Studies | Methods for promoting hair growth |
JP5837748B2 (ja) * | 2007-12-31 | 2015-12-24 | リアル イメージング リミテッド | 撮像データのレジストレーションのためのシステムおよび方法 |
US8620041B2 (en) * | 2007-12-31 | 2013-12-31 | Real Imaging Ltd. | Method apparatus and system for analyzing thermal images |
WO2009118721A1 (en) * | 2008-03-28 | 2009-10-01 | Real Imaging Ltd. | Method apparatus and system for analyzing thermal images |
US8663210B2 (en) | 2009-05-13 | 2014-03-04 | Novian Health, Inc. | Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy |
WO2011054811A1 (en) | 2009-11-03 | 2011-05-12 | Santaris Pharma A/S | Rna antagonists targeting hsp27 combination therapy |
WO2011057248A2 (en) | 2009-11-09 | 2011-05-12 | Genvec, Inc. | Simian adenovirus and methods of use |
WO2011074564A1 (ja) * | 2009-12-15 | 2011-06-23 | タカラバイオ株式会社 | アデノウイルスベクターの製造方法 |
EP3191131A4 (de) | 2014-08-21 | 2018-09-05 | The General Hospital Corporation | Tumornekrosefaktor-superfamilie und tnf-like-ligand-muteine sowie verfahren zur herstellung und verwendung davon |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5288852A (en) * | 1984-03-06 | 1994-02-22 | Dainippon Pharmaceutical Co., Ltd. | Human tumor necrosis factor polypeptides |
EP0155549B1 (de) | 1984-03-06 | 1991-03-20 | Dainippon Pharmaceutical Co., Ltd. | DNS den menschlichen Tumornekrosisfaktor kodierend und das menschliche Tumornekronisfaktor-Polypeptid |
US4879226A (en) * | 1984-04-06 | 1989-11-07 | Asahi Kasei Kogyo Kabushiki Kaisha | Novel human physiologically active polypeptide |
US5662896A (en) | 1988-03-21 | 1997-09-02 | Chiron Viagene, Inc. | Compositions and methods for cancer immunotherapy |
US5763209A (en) * | 1988-09-26 | 1998-06-09 | Arch Development Corporation | Methods and materials relating to the functional domains of DNA binding proteins |
US5206152A (en) * | 1988-04-08 | 1993-04-27 | Arch Development Corporation | Cloning and expression of early growth regulatory protein genes |
US5698531A (en) * | 1989-03-31 | 1997-12-16 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
EP0897987B1 (de) * | 1989-10-24 | 2001-02-28 | Chiron Corporation | Sekretion vom mit Gamma-Interferon Signalpeptid gebundenen humänen Protein |
CA2055168A1 (en) * | 1990-11-21 | 1992-05-22 | Walter Fiers | Tnf-muteins |
AU657111B2 (en) * | 1990-12-20 | 1995-03-02 | Dana-Farber Cancer Institute | Control of gene expression by ionizing radiation |
US6605712B1 (en) * | 1990-12-20 | 2003-08-12 | Arch Development Corporation | Gene transcription and ionizing radiation: methods and compositions |
US5358866A (en) * | 1991-07-03 | 1994-10-25 | The United States Of America As Represented By The Department Of Health And Human Services | Cytosine deaminase negative selection system for gene transfer techniques and therapies |
FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
US5968735A (en) * | 1992-11-12 | 1999-10-19 | Max Delbruck-Centrum Fur Molekular Medizin Berlin | Vector for the expression of therapy-relevant genes |
US5271207A (en) * | 1992-11-18 | 1993-12-21 | Moshe Epstein | Dual-function nozzle head for vacuum-packaging tooling |
US5801029A (en) * | 1993-02-16 | 1998-09-01 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
FR2709309B1 (fr) | 1993-08-25 | 1995-11-10 | Centre Nat Rech Scient | Compositions cellulaires, préparation et utilisations thérapeutiques. |
US5631236A (en) * | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
US5641755A (en) * | 1994-02-04 | 1997-06-24 | Arch Development Corp. | Regulation of x-ray mediated gene expression |
US5571797A (en) * | 1994-05-11 | 1996-11-05 | Arch Development Corporation | Method of inducing gene expression by ionizing radiation |
WO1995034671A1 (en) | 1994-06-10 | 1995-12-21 | Genvec, Inc. | Complementary adenoviral vector systems and cell lines |
US5851806A (en) * | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
US7592317B1 (en) * | 1994-08-11 | 2009-09-22 | The University Of Chicago | Constitutive gene expression in conjuction with ionizing radiation |
US5962424A (en) * | 1995-02-21 | 1999-10-05 | Arch Development Corporation | Methods and compositions for targeting selectins |
WO1996027021A1 (en) | 1995-03-01 | 1996-09-06 | Cornell Research Foundation, Inc. | Interdependent adenoviral vectors and methods of using same |
AU5634696A (en) | 1995-04-28 | 1996-11-18 | Genetic Therapy, Inc. | Treatment of tumors with cells expressing interferons, tumor necrosis factors, or other cytokines |
US6281010B1 (en) * | 1995-06-05 | 2001-08-28 | The Trustees Of The University Of Pennsylvania | Adenovirus gene therapy vehicle and cell line |
US5993800A (en) * | 1995-06-05 | 1999-11-30 | Bristol-Myers Squibb Company | Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligand |
US6254862B1 (en) * | 1997-03-03 | 2001-07-03 | Calydon, Inc. | Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof |
WO1997012623A1 (en) | 1995-10-06 | 1997-04-10 | Arch Development Corporation | Methods and compositions for viral enhancement of cell killing |
EA199800475A1 (ru) | 1995-11-28 | 1998-12-24 | Дженвек, Инк. | Векторы и способы для переноса генов в клетки |
WO1997039135A1 (en) | 1996-04-17 | 1997-10-23 | Board Of Regents, The University Of Texas System | Enhanced expression of transgenes |
DE69740033D1 (de) | 1996-07-03 | 2010-12-09 | Merial Inc | Rekombinanter hunde-adenovirus 2 (cav2), welcher exogene dna enthält |
CA2232743A1 (en) | 1997-04-02 | 1998-10-02 | Smithkline Beecham Corporation | A tnf homologue, tl5 |
US5981275A (en) | 1997-04-14 | 1999-11-09 | Genzyme Corporation | Transgene expression system for increased persistence |
US6100086A (en) | 1997-04-14 | 2000-08-08 | Genzyme Corporation | Transgene expression systems |
IL120979A0 (en) | 1997-06-02 | 1997-11-20 | Interpharm Lab Ltd | Glycosylated TNF |
US6171787B1 (en) | 1997-06-26 | 2001-01-09 | Abbott Laboratories | Member of the TNF family useful for treatment and diagnosis of disease |
AU9673998A (en) | 1997-10-01 | 1999-04-23 | G.D. Searle & Co. | Fusion proteins comprising an angiostatin moiety and their use in anti-tumor treatment |
EP1027076A2 (de) | 1997-10-29 | 2000-08-16 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Verwendung von vektoren wie adenoviren und/oder adeno-assoziierten viren und/oder retroviren und/oder herpes-simplex-viren und/oder liposomen und/oder plasmiden als vehikel für genetische information zur befähigung von säugetierzellen mittel, zur behandlung von knochenpathologien zu produzieren |
DE19747718A1 (de) | 1997-10-29 | 1999-05-06 | Baltzer Axel Wilhelm August Dr | Verfahren zur Therapie knochenresorbierender Erkrankungen mit der molekularbiologischen Methode der Gentherapie |
BR9813917A (pt) | 1997-11-03 | 2001-10-30 | Univ Arizona | Vetores de expressão induzìveis hipertérmicospara terapia de genetica e métodos de uso dos mesmos |
WO1999046371A2 (en) | 1998-03-11 | 1999-09-16 | Board Of Regents, The University Of Texas System | Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery |
WO1999047690A2 (en) | 1998-03-16 | 1999-09-23 | Introgen Therapeutics, Inc. | Multigene vectors |
AU772963B2 (en) | 1998-04-24 | 2004-05-13 | Onyx Pharmaceuticals | Adenoviral vectors for treating disease |
EP1087785A2 (de) | 1998-06-15 | 2001-04-04 | Arch Development Corporation | Kombination von strahlentherapie und anti-angigene faktoren |
IL126757A0 (en) | 1998-09-07 | 1999-08-17 | Yissum Res Dev Co | Regulation of gene expression through manipulation of mRNA splicing and its uses |
US6440944B2 (en) | 1998-10-16 | 2002-08-27 | Genvec, Inc. | Methods of administering adenoviral vectors |
US6337338B1 (en) * | 1998-12-15 | 2002-01-08 | Telik, Inc. | Heteroaryl-aryl ureas as IGF-1 receptor antagonists |
US6495130B1 (en) | 1998-12-30 | 2002-12-17 | Calydon, Inc. | Target cell-specific adenoviral vectors containing E3 and methods of use thereof |
PT1135514E (pt) | 1999-01-28 | 2009-07-20 | Onyx Pharma Inc | Vectores de vaivém adenovirais com deleção em e1b |
AU7862600A (en) | 1999-10-07 | 2001-05-10 | Carlos Estuardo Aguilar-Cordova | Methods for treatment of solid tumors and metastasis by gene therapy |
US6579522B1 (en) | 2000-06-27 | 2003-06-17 | Genvec, Inc. | Replication deficient adenoviral TNF vector |
JP2004532213A (ja) | 2001-04-06 | 2004-10-21 | ザ ユニヴァーシティ オヴ シカゴ | Egr−1プロモーター活性の化学療法誘導 |
US20030086903A1 (en) * | 2001-11-02 | 2003-05-08 | Genvec, Inc. | Therapeutic regimen for treating cancer |
-
2001
- 2001-11-02 US US10/001,017 patent/US20030086903A1/en not_active Abandoned
-
2002
- 2002-05-17 US US10/151,633 patent/US7214368B2/en not_active Expired - Fee Related
- 2002-11-01 CA CA002465361A patent/CA2465361A1/en not_active Abandoned
- 2002-11-01 EP EP02776411A patent/EP1455840B1/de not_active Expired - Lifetime
- 2002-11-01 WO PCT/US2002/035042 patent/WO2003039458A2/en active Application Filing
- 2002-11-01 JP JP2003541750A patent/JP2005536447A/ja active Pending
- 2002-11-01 AT AT02776411T patent/ATE419875T1/de not_active IP Right Cessation
- 2002-11-01 DE DE60230807T patent/DE60230807D1/de not_active Expired - Lifetime
-
2007
- 2007-04-02 US US11/695,437 patent/US20070166284A1/en not_active Abandoned
-
2010
- 2010-08-12 US US12/855,050 patent/US20100305199A1/en not_active Abandoned
-
2012
- 2012-04-05 US US13/439,915 patent/US20120203052A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2465361A1 (en) | 2003-05-15 |
JP2005536447A (ja) | 2005-12-02 |
ATE419875T1 (de) | 2009-01-15 |
EP1455840A2 (de) | 2004-09-15 |
WO2003039458A3 (en) | 2003-11-20 |
EP1455840B1 (de) | 2009-01-07 |
US7214368B2 (en) | 2007-05-08 |
EP1455840A4 (de) | 2004-12-15 |
WO2003039458A2 (en) | 2003-05-15 |
US20100305199A1 (en) | 2010-12-02 |
US20030086904A1 (en) | 2003-05-08 |
US20030086903A1 (en) | 2003-05-08 |
US20120203052A1 (en) | 2012-08-09 |
US20070166284A1 (en) | 2007-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE419875T1 (de) | Behandlung von sarkom bei menschen mit adenovirus-vektor tnf-alpha | |
DE602004025726D1 (de) | Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc). | |
DE60023476D1 (de) | Kombination von doctaxel und rhumab her2 zür krebsbehandlung | |
ATE186219T1 (de) | Kombination von antihormonale und bindende moleküle zur krebsbehandlung | |
CY1107578T1 (el) | Πεπτιδια που χρησιμευουν στη θepαπεια ογκων και αλλων καταστασεων που χρηζουν την αφαιρεση ή την καταστροφη κυτταρων | |
EA200300294A1 (ru) | Способы лечения связанного с bcl-2 нарушения с использованием bcl-2-антисмысловых олигомеров | |
DE69731540D1 (de) | Behandlung von diarrhoe | |
DE69630890D1 (de) | Peptid-immitierende substanzen in der krebstherapie | |
ATE302020T1 (de) | Verwendung von copolymer 1- und verwandten peptiden sowie von polypeptiden und damit behandelten t-zellen zur neuroprotektiven therapie | |
NZ504026A (en) | Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C | |
DE69703689D1 (de) | Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia | |
DE69426334D1 (de) | Parenterales Busulfan zur Behandlung von malignen Krankheiten | |
BR9813318A (pt) | Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário | |
ATE382061T1 (de) | Mittel zur induktion von apoptosis und zur therapieanwendung | |
ATE307886T1 (de) | Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung | |
WO2000040229A3 (en) | Synergistic tumorcidal response induced by histamine | |
DE60116075D1 (de) | Behandlung von tumoren mit photodynamischer therapie | |
WO2004056971A3 (en) | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers | |
MXPA00010254A (es) | Tratamiento de disfuncion sexual en ciertos grupos de pacientes. | |
ATE291918T1 (de) | Kombinationstherapie zur behandlung von tumoren | |
WO1996020950A3 (en) | Compositions and methods for treating rheumatoid arthritis | |
EP1143996A4 (de) | Methode zur behandlung von chronischen herzerkrankungen | |
DE60230641D1 (de) | Lentivirale vektoren zur behandlung von schmerzen | |
WO2023164455A3 (en) | Compositions and methods to modulate the immune system | |
DE69803052T2 (de) | Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |